Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer.

Bauden, Monika LU orcid ; Pamart, Dorian ; Ansari, Daniel LU ; Herzog, Marielle ; Eccleston, Mark ; Micallef, Jake ; Andersson, Bodil LU orcid and Andersson, Roland LU (2015) In Clinical Epigenetics 7.
Abstract
To improve the prognosis of patients with pancreatic cancer, new biomarkers are required for earlier, pre-symptomatic diagnosis. Epigenetic mutations take place at the earliest stages of tumorigenesis and therefore offer new approaches for detecting and diagnosing disease. Nucleosomes are the repeating subunits of DNA and histone proteins that constitute human chromatin. Because of their release into the circulation, intact nucleosome levels in serum or plasma can serve as diagnostic disease biomarkers, and elevated levels have been reported in various cancers. However, quantifying nucleosomes in the circulation for cancer detection has been challenging due to nonspecific elevation in sera of patients with benign diseases. Here, we report... (More)
To improve the prognosis of patients with pancreatic cancer, new biomarkers are required for earlier, pre-symptomatic diagnosis. Epigenetic mutations take place at the earliest stages of tumorigenesis and therefore offer new approaches for detecting and diagnosing disease. Nucleosomes are the repeating subunits of DNA and histone proteins that constitute human chromatin. Because of their release into the circulation, intact nucleosome levels in serum or plasma can serve as diagnostic disease biomarkers, and elevated levels have been reported in various cancers. However, quantifying nucleosomes in the circulation for cancer detection has been challenging due to nonspecific elevation in sera of patients with benign diseases. Here, we report for the first time differential, disease-associated epigenetic profiles of intact cell-free nucleosomes (cfnucleosomes) containing specific DNA and histone modifications as well as histone variants circulating in the blood. The study comprised serum samples from 59 individuals, including 25 patients with resectable pancreatic cancer, 10 patients with benign pancreatic disease, and 24 healthy individuals using Nucleosomics(®), a novel ELISA method. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Clinical Epigenetics
volume
7
article number
106
publisher
BioMed Central (BMC)
external identifiers
  • pmid:26451166
  • wos:000362406200001
  • scopus:84943147333
  • pmid:26451166
ISSN
1868-7075
DOI
10.1186/s13148-015-0139-4
project
Pancreatic cancer
language
English
LU publication?
yes
id
105aa9fc-0ead-4f51-b5b3-03fea0bcb879 (old id 8158479)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26451166?dopt=Abstract
date added to LUP
2016-04-01 10:47:57
date last changed
2022-04-28 01:28:54
@article{105aa9fc-0ead-4f51-b5b3-03fea0bcb879,
  abstract     = {{To improve the prognosis of patients with pancreatic cancer, new biomarkers are required for earlier, pre-symptomatic diagnosis. Epigenetic mutations take place at the earliest stages of tumorigenesis and therefore offer new approaches for detecting and diagnosing disease. Nucleosomes are the repeating subunits of DNA and histone proteins that constitute human chromatin. Because of their release into the circulation, intact nucleosome levels in serum or plasma can serve as diagnostic disease biomarkers, and elevated levels have been reported in various cancers. However, quantifying nucleosomes in the circulation for cancer detection has been challenging due to nonspecific elevation in sera of patients with benign diseases. Here, we report for the first time differential, disease-associated epigenetic profiles of intact cell-free nucleosomes (cfnucleosomes) containing specific DNA and histone modifications as well as histone variants circulating in the blood. The study comprised serum samples from 59 individuals, including 25 patients with resectable pancreatic cancer, 10 patients with benign pancreatic disease, and 24 healthy individuals using Nucleosomics(®), a novel ELISA method.}},
  author       = {{Bauden, Monika and Pamart, Dorian and Ansari, Daniel and Herzog, Marielle and Eccleston, Mark and Micallef, Jake and Andersson, Bodil and Andersson, Roland}},
  issn         = {{1868-7075}},
  language     = {{eng}},
  publisher    = {{BioMed Central (BMC)}},
  series       = {{Clinical Epigenetics}},
  title        = {{Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer.}},
  url          = {{https://lup.lub.lu.se/search/files/2143663/8840926}},
  doi          = {{10.1186/s13148-015-0139-4}},
  volume       = {{7}},
  year         = {{2015}},
}